KR20010068833A - Miscible composition containing extract of black cohosh - Google Patents

Miscible composition containing extract of black cohosh Download PDF

Info

Publication number
KR20010068833A
KR20010068833A KR1020000000948A KR20000000948A KR20010068833A KR 20010068833 A KR20010068833 A KR 20010068833A KR 1020000000948 A KR1020000000948 A KR 1020000000948A KR 20000000948 A KR20000000948 A KR 20000000948A KR 20010068833 A KR20010068833 A KR 20010068833A
Authority
KR
South Korea
Prior art keywords
extract
weight
polyethylene glycol
mixing
riding
Prior art date
Application number
KR1020000000948A
Other languages
Korean (ko)
Other versions
KR100366233B1 (en
Inventor
노재일
홍성욱
한정화
Original Assignee
노재일
이용화
한정화
진양제약주식회사
홍성욱
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노재일, 이용화, 한정화, 진양제약주식회사, 홍성욱 filed Critical 노재일
Priority to KR10-2000-0000948A priority Critical patent/KR100366233B1/en
Publication of KR20010068833A publication Critical patent/KR20010068833A/en
Application granted granted Critical
Publication of KR100366233B1 publication Critical patent/KR100366233B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE: A mixing process for Cimicifugae Rhizoma extract and mixed composition thereof are provided, which show improved rate of drug release, bioabsorption rate, and therapeutic effect. CONSTITUTION: The mixing process for the Cimicifugae Rhizoma extract is comprised of: soaking Cimicifugae Rhizoma in 50vol.% of ethanol, compressing the extract, and obtaining the extracted solution; mixing 30-90wt.% of polyethylene glycol 400 and 5- 20wt.% of conc.glycerin in another vessel, adding 5-15wt.% of distilled water, heating, and homogenizing by mixing at 60deg.C; adding 2-40wt.% of Cimicifugae Rhizoma extract, and mixing uniformly while shaking at 1500rpm; cooling to normal temperature while shaking slowly, removing the foam, and producing the mixed composition; and manufacturing capsules by the common process.

Description

승마추출물의 혼화방법 및 그 혼화된 조성물{Miscible composition containing extract of black cohosh}Miscible composition containing extract of black cohosh

본 발명은 천연 식물성 호르몬인 승마(升痲 : Cimicifugae rhyzoma)추출물을 혼화시키는 방법, 그 혼화된 조성물 및 이의 연질갑셀제에 관한 것이다. 보다 상세히 하면, 본 발명은 승마추출물을 폴리에틸렌글리콜, 농글리세린 및 정제수의 혼합용매에 첨가함을 특징으로 하는 승마추출물의 혼화 방법, 그 혼화된 조성물 및 이 조성물을 함유하는 연질캅셀제에 관한 것이다.The present invention relates to a method of admixing horseback (Cimicifugae rhyzoma) extract, a natural plant hormone, the mixed composition thereof and a soft-gaxel agent thereof. More specifically, the present invention relates to a method for admixing a horse riding extract, a mixed composition thereof, and a soft capsule containing the composition, wherein the horse riding extract is added to a mixed solvent of polyethylene glycol, concentrated glycerin, and purified water.

승마(Black Cohosh, 학명 : Cimicifugae, 생약명 : 승마)의 정량 추출물인 승마추출물(주활성성분으로서 27-데옥시악테인(deoxyacteine) 함유)은 갱년기 여성의 제반 증상을 치료하는데 매우 유용한 물질이다. 여성은 폐경 연령(40∼50대)에 이르면 특징적인 여러 증상(홍조, 발한, 우울증, 월경장애 등)을 겪게 되는데 이는 난소에서 분비되는 에스트로겐의 혈중농도가 급격히 감소되기 때문에 나타나는 증상이다.Equestrian extract (a 27-deoxyacteine as the main active ingredient), a quantitative extract of horse riding (Black Cohosh, scientific name: Cimicifugae, herbal name: horse riding), is very useful for treating all symptoms of menopausal women. When women reach the age of menopause (forty to fifties), they experience various symptoms (flushing, sweating, depression, dysmenorrhea, etc.), which are caused by a sharp decrease in blood levels of estrogen secreted by the ovaries.

아메리카 인디언들이 여성 질환에 주로 사용한 기원을 지닌 승마추출물은 여성 호르몬 대체 작용과 함께 황체 자극호르몬을 직접 차단하는 작용을 지니고 있으며 타 호르몬제의 부작용으로 인해 치료를 중단한 경우에도 사용할 수 있는 이상적인 HRT(호르몬 대체 치료 : Hormone Replacement Therapy)제제이다.Horseback Riding Extract, which is primarily used by American Indians for women's diseases, has the effect of directly replacing the luteal stimulating hormone with female hormone replacement, and is an ideal HRT that can be used even when treatment is discontinued due to the adverse effects of other hormones. Hormone Replacement Therapy

천연 식물성 호르몬인 승마추출물은 여성 체내의 에스트로겐 혈중농도에 따라 에스트로겐치를 조정해 주는 조정 작용을 지니고 있기 때문에 유방암, 자궁암 등의 여성에 치명적인 부작용이 없다.Equestrian extract, a natural plant hormone, has an effect of adjusting estrogen levels according to blood levels of estrogen in a woman's body. Therefore, there is no fatal side effect for women such as breast cancer and uterine cancer.

대체 호르몬 요법의 적용방향 중 하나는 안전하고 호르몬과 같은 신속한 약효의 발현에 있는데 현재는 정제의 형태로 시판되고 있다. 그러나 승마추출물은 원료 생약으로부터 50% 에탄올로 정량 추출되기 때문에 이를 정제로 제형화 하였을 때 액체 상태의 승마추출물과 고체상태의 다른 원료와의 배합에 있어서 엉김과 부착에 의한 문제가 나타날 수 있으며 이로 인한 낮은 용출률과 역가의 저하, 이로 인한 생체이용률의 저하가 나타날 수 있다.One application of alternative hormone therapy is the safe and fast expression of hormone-like drugs, which are currently marketed in the form of tablets. However, since the horse riding extract is quantitatively extracted from the raw herbal medicine with 50% ethanol, when it is formulated as a tablet, there may be a problem due to entanglement and adhesion in mixing the horse riding extract in the liquid state with other raw materials in the solid state. Low dissolution rates and lower titers can result in lower bioavailability.

본 발명에서는 상기와 같은 기존 제형의 낮은 용출률과 역가의 저하를 개선하고자 약물 용출률을 크게 향상시켜 인체 흡수율을 크게 높인 승마추출물의 혼화방법, 그 혼화된 조성물 및 이를 함유하는 연질캅셀을 발명하였다.In the present invention, in order to improve the low dissolution rate and lower the titer of the conventional formulation as described above, the drug dissolution rate was greatly improved, and the method for admixing a riding extract having a high human absorption rate, the mixed composition, and a soft capsule containing the same were invented.

본 발명에서는 폴리에틸렌글리콜과 수용성 기제에 승마추출물을 혼화시키는 방법으로 연질캅셀제형을 설계하여 용출률을 크게 향상시켰다.In the present invention, a soft capsule formulation was designed by mixing a polyethylene glycol and a horse riding extract in a water-soluble base to greatly improve the dissolution rate.

따라서, 본 발명의 목적은 승마추출물을 수용성 기제에 혼화시킨 혼화 조성물 및 그 제조방법을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a miscible composition in which a horse riding extract is miscible with a water-soluble base and a method for producing the same.

본 발명의 다른 목적은 상기 혼화성 승마추출물 함유 조성물의 연질캅셀제를제공하는 것이다.Another object of the present invention to provide a soft capsule of the miscible horse riding extract containing composition.

다음에 본 발명을 상세히 설명한다.Next, the present invention will be described in detail.

본 발명의 승마추출물의 혼화조성물은, 폴리에틸렌글리콜, 농글리세린 및 정제수로 이루어지는 혼화기제에 승마추출물을 혼화시켜 제조할 수 있다.The miscible composition of the equestrian extract of the present invention can be prepared by admixing the equestrian extract with a miscation base composed of polyethylene glycol, concentrated glycerin and purified water.

더욱 상세히 하면, 본 발명의 승마추출물의 혼화 조성물은, 전체중량대비, 승마추출물 2∼40 중량%(27-데옥시악테인으로서 0.1∼2 중량%), 폴리에틸렌글리콜 30∼90 중량%, 농글리세린 5∼20 중량% 및 정제수 5∼15 중량%를 혼합하여 제조된다. 이때 상기 조성물에서 승마추출물의 함량은 승마원료를 50 용량% 에탄올추출물을 기준으로 한다.More specifically, the mixed composition of the horse riding extract of the present invention, 2 to 40% by weight of the horse riding extract (0.1 to 2% by weight as 27-deoxyactin), 30 to 90% by weight polyethylene glycol, concentrated glycerin It is prepared by mixing 5 to 20% by weight and 5 to 15% by weight of purified water. At this time, the content of the horse riding extract in the composition is based on 50% by volume ethanol extract of the riding raw material.

본 발명에서는 승마추출물 중 27-데옥시악테인을 0.1∼2 중량%까지를 혼화시킬 수 있으며 약물효과의 발현을 위해서 좋게는 0.1∼1 중량%까지 승마추출물 중 27-데옥시악테인 사용량에 따라 혼화하여 용출시험을 하였다.In the present invention, 27-deoxyactin may be mixed in 0.1 to 2% by weight of horseback extract, and preferably, 0.1 to 1% by weight of 27-deoxyactin in horseback extract for the expression of drug effects. It was mixed and the dissolution test was performed.

여기서 수용성기제로 폴리에틸렌글리콜, 정제수, 농글리세린을 사용하였으며, 주된 기제인 폴리에틸렌글리콜로서는 폴리에틸렌글리콜 400이 바람직하였다. 이 때 폴리에틸렌글리콜의 사용량은 30∼90 중량%이고, 더욱 바람직하게는 60∼80 중량%를 사용하는 것이 좋다.Polyethylene glycol, purified water, and concentrated glycerin were used as the water-soluble base, and polyethylene glycol 400 was preferable as the polyethylene glycol as the main base. At this time, the amount of polyethylene glycol used is 30 to 90% by weight, more preferably 60 to 80% by weight.

또한 정제수 사용량은 5∼15 중량%, 더욱 바람직하게는 5∼11 중량%, 농글리세린은 5∼20 중량%, 더욱 바람직하게는 8∼15 중량%를 사용하여 혼합된 액을 만들어 수용성 용매계로 구성하였다.In addition, the amount of purified water used is 5 to 15% by weight, more preferably 5 to 11% by weight, concentrated glycerin is 5 to 20% by weight, more preferably 8 to 15% by weight to form a mixed solution to form a water-soluble solvent system It was.

상기에서 정제수는 폴리에틸렌글리콜과 농글리세린의 계면활성력을 향상시킬 수 있으며, 정제수와 글리세린 사용량을 25 중량부 이상을 사용하면 캅셀 피막이 연화되고 보관 중 피막의 경시변화 발생의 문제가 있어 좋지 않다.The purified water may improve the interfacial activity of polyethylene glycol and concentrated glycerin, and when the amount of purified water and glycerin is used in an amount of 25 parts by weight or more, the capsule film is softened and there is a problem of the change of the film over time during storage.

본 발명에서 상기의 성분들을 사용한 내용약물의 조제방법은 먼저 농글리세린, 폴리에틸렌글리콜을 혼합한 다음 정제수를 투입하고 가온하여 약 60℃ 온도에서 혼합시킨 후 60℃ 온도를 유지한 상태에서 승마엑스 원료를 서서히 투입하고 교반하여 균일하게 혼합한 후 서서히 교반시키면서 실온의 상태로 냉각한 다음 진공펌프를 사용하여 기포를 제거하여 연질캅셀의 내용물을 얻는다.In the present invention, the preparation method of the drug substance using the above ingredients is first mixed with concentrated glycerin, polyethylene glycol and then added purified water and warmed to mix at about 60 ℃ temperature and then maintained at 60 ℃ temperature riding X raw material Slowly add, stir and uniformly mix, cool to room temperature with slow stirring, and then remove the air bubbles using a vacuum pump to obtain the contents of the soft capsule.

본 발명에서의 연질캅셀 피막은 일반적으로 사용하는 젤라틴, 가소제의 소프트 겔처방으로 통상의 제조방법으로 제조한다. 또한 본 발명의 승마추출물을 함유한 연질갑셀은 현재 일반적 방법인 로타리식 자동충진기를 사용하여 통상의 충진방법으로 성형한 다음 건조 및 선별공정을 거쳐 시제품으로 한다.The soft capsule coating in the present invention is produced by a conventional manufacturing method by soft gel prescription of gelatin and plasticizer generally used. In addition, the soft carapace containing the horse riding extract of the present invention is molded into a conventional filling method using a rotary automatic filling machine which is a common method, and then dried and sorted to produce a prototype.

또한 본 발명으로 제조된 연질캅셀제는 기존 시판 승마추출물 함유 정제에 비해 월등히 우수한 용출률을 나타내었다. 따라서 본 발명의 효과는 종래의 제형에 비해 우수한 용출률과 높은 인체흡수율을 지닌 제형을 발명한 것이다.In addition, the soft capsule prepared according to the present invention showed an excellent dissolution rate compared to conventional commercial riding extract containing tablets. Therefore, the effect of the present invention is to invent a formulation having excellent dissolution rate and high human absorption rate compared to the conventional formulation.

승마추출액의 추출방법은 다음과 같다.The extraction method of horse riding extract is as follows.

원료 생약 승마를 50용량% 에탄올, 50 용량% 이소프로판올, 50용량% 메탄올, 에테르, 정제수에서 선택된 용매로 침출시킨 후 추출물을 꺼내어 압착하여 추출액을 얻는다. 상기의 추출액중 50 용량% 에탄올을 사용한 경우 27-데옥시악테인의 함량이 제일 우수하였다.Raw herbal riding is leached with a solvent selected from 50 vol% ethanol, 50 vol% isopropanol, 50 vol% methanol, ether, purified water, and then the extract is extracted and compressed to obtain an extract. When 50 vol% ethanol was used in the extract, the content of 27-deoxyactin was the best.

제조예 1Preparation Example 1

원료 생약 승마를 50 용량% 에탄올로 침출시킨 후 추출물을 꺼내어 압착하여 추출액을 얻었다. 이 액 1 ml중 27-데옥시악테인의 함량은 31.67mg이다.Raw herbal riding was leached with 50% by volume ethanol, and then the extract was taken out and compressed to obtain an extract. The content of 27-deoxyactin in 1 ml of this solution is 31.67 mg.

제조예 2Preparation Example 2

원료 생약 승마를 50 용량% 이소프로판올로 침출시킨 후 추출물을 꺼내어 압착하여 추출액을 얻었다. 이 액 1 ml중 27-데옥시악테인의 함량은 29.74mg이다.Raw herbal riding was leached with 50% by volume isopropanol, and then the extract was taken out and pressed to obtain an extract. The content of 27-deoxyactin in 1 ml of this solution is 29.74 mg.

제조예 3Preparation Example 3

원료 생약 승마를 50 용량% 메탄올로 침출시킨 후 추출물을 꺼내어 압착하여 추출액을 얻었다. 이 액 1 ml중 27-데옥시악테인의 함량은 25.44mg이다.Raw herbal riding was leached with 50% by volume methanol, and then the extract was taken out and compressed to obtain an extract. The content of 27-deoxyactin in 1 ml of this solution is 25.44 mg.

제조예 4Preparation Example 4

원료 생약 승마를 에테르로 침출시킨 후 추출물을 꺼내어 압착하여 추출액을 얻었다. 이 액 1 ml중 27-데옥시악테인의 함량은 12.76mg이다.Raw material horseback riding was leached with ether, and then the extract was taken out and pressed to obtain an extract. The content of 27-deoxyactin in 1 ml of this solution is 12.76 mg.

제조예 5Preparation Example 5

원료 생약 승마를 정제수로 침출시킨 후 추출물을 꺼내어 압착하여 추출액을 얻었다. 이 액 1 ml중 27-데옥시악테인의 함량은 18.25mg이다.Raw material horseback riding was leached with purified water, and the extract was taken out and compressed to obtain an extract. The content of 27-deoxyactin in 1 ml of this solution is 18.25 mg.

이하 승마추출물 함유 정제와 연질캅셀제의 용출률 시험 결과 비교를 통하여 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail by comparing the dissolution rate test results of the tablet containing the riding extract and the soft capsule.

실시예 : 승마추출물 함유 혼화조성물 및 연질캅셀의 제조Example: Preparation of Horse Riding Extract-Containing Mixed Composition and Soft Capsule

다음 조성으로 승마추출물의 연질캅셀제를 제조하였다.The soft capsule of the horse riding extract was prepared with the following composition.

·1캅셀 내용물 중1 capsule content

승마추출물 ···························0.0286 mLHorse Riding Extract ················· 0.0286 mL

(27-데옥시악테인으로서 1.0 mg)(1.0 mg as 27-deoxyactin)

폴리에틸렌글리콜 400························390 mgPolyethylene glycol 400 ... 390 mg

농글리세린 ·····························55 mgConcentrated glycerin · ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 55 mg

정제수 ·······························35 mgPurified water ... 35 mg

계·································500 mg500mg mg

본 발명의 약물의 조제방법은 먼저 폴리에틸렌글리콜400 1950 g과 농글리세린 275 g을 혼합한 다음 정제수 175 g을 투입하고 가온하여 약 60℃에서 혼합하여 균질화한다. 이 혼합물을 약 60℃로 유지한 상태에서 승마추출물 143 mL를 서서히 투입하고 교반기로 약 1,500rpm으로 교반하면서 균일하게 혼합을 한 후 서서히 교반하면서 실온으로 냉각하고 진공펌프를 사용하여 기포를 제거하고 연질캅셀의 내용물로 한다.In the preparation method of the drug of the present invention, first, 1950 g of polyethylene glycol 400 and 275 g of concentrated glycerin are mixed, and then 175 g of purified water is added thereto, warmed, and mixed at about 60 ° C. for homogenization. 143 mL of the equestrian extract was slowly added while maintaining the mixture at about 60 ° C., and the mixture was mixed uniformly while stirring at about 1,500 rpm with a stirrer, and then cooled slowly to room temperature with gentle stirring, and bubbles were removed by using a vacuum pump. It is set as the contents of a capsule.

본 발명에서의 연질캅셀의 피막은 일반적으로 널리 알려진 젤라틴, 가소제의 소프트겔처방으로 하여 1캅셀 당 젤라틴 132 mg, 농글리세린 52 mg, 디소르비톨액 70% 6 mg 및 착향제로 에틸바닐린 적당량, 코팅기제로 카르나우바납과 분획야자유 적당량을 사용하여 통상의 조제방법으로 조제한다.In the present invention, the soft capsule film is generally used as a soft gel of gelatin and plasticizer, which is widely known, and gelatin 132 mg per capsule, concentrated glycerin 52 mg, dissorbitol 70% 6 mg, and an appropriate amount of ethyl vanillin as a flavoring agent, a coating machine. It is prepared by a conventional preparation method using an appropriate amount of zero carnauba wax and fractionated palm oil.

본 발명의 승마추출물 함유 연질캅셀의 생산은 일반적으로 사용하고 있는 로타리식 자동충진기를 이용하여 통상의 충진방법으로 오발 10 타입(Oval 10 type)에 성형한 다음 건조 및 선별공정을 거쳐 시제품으로 한다.Production of the soft capsule containing the horse riding extract of the present invention is molded into an Oval 10 type by a conventional filling method using a rotary automatic filling machine, which is generally used, and then dried and screened to be a prototype.

실험예 : 용출률 실험 및 비교평가Experimental Example: Dissolution Rate Experiment and Comparative Evaluation

승마추출물 함유 시판정제(상품명 : 훼라민정, 제조사 : 동국제약(주))와 연질캅셀의 용출시험은 USP23판과 대한약전의 용출시험법 제2법(paddle법)에 따라 100rpm으로 60분 동안 25% 염산 10 mL에 물을 넣어 1L로 한 액(pH1.2)과 0.2M 인산이수소칼륨액 250 mL와 0.2N 수산화나트륨액 118 mL 혼합액에 물을 넣어 1L로 한 액(pH6.8) 900 mL를 각각 시험액으로 하여 pH에 따른 용출시험을 한 후 용출액을 여과하여 농축한 것을 검액으로 하고 흡광도법에 따라 함량을 측정하였다. 용출률 시험 결과를 다음 표 1 및 2에 나타낸다.The dissolution test of commercially available tablets containing horse riding extract (trade name: Ferramin tablet, manufacturer: Dongkuk Pharmaceutical Co., Ltd.) and soft capsule was carried out for 25 minutes at 100 rpm for 60 minutes at 100 rpm according to the USP23 version and the dissolution test method 2 (paddle method). % 10 ml of hydrochloric acid (pH1.2) with 1 liter of water and 250 ml of 0.2 M potassium dihydrogen phosphate and 118 ml of 0.2 N sodium hydroxide solution (1 mL) to add 1 liter of water (pH6.8) 900 Dissolve the elution test according to pH using each mL as the test solution, and the eluate was concentrated by filtration. The content was measured according to the absorbance method. The dissolution rate test results are shown in Tables 1 and 2 below.

pH 1.2에서의 승마추출물 함유 정제와 연질캅셀제 용출률 시험 결과Elution test results of tablets containing riding extract at pH 1.2 and soft capsules 시 간time Tab.Tab. S.Cap.S.Cap. 55 3.1±0.32 %3.1 ± 0.32% 13.8±6.55 %13.8 ± 6.55% 1010 5.2±0.48 %5.2 ± 0.48% 87.6±4.33 %87.6 ± 4.33% 2020 15.6±3.42 %15.6 ± 3.42% 99.8±0.45 %99.8 ± 0.45% 3030 35.7±5.52 %35.7 ± 5.52% 99.9±0.24 %99.9 ± 0.24% 4040 55.3±7.62 %55.3 ± 7.62% 101.3±2.5 %101.3 ± 2.5% 6060 78.3±10.64 %78.3 ± 10.64% 100.5±1.2 %100.5 ± 1.2%

pH 6.8에서의 승마추출물 함유 정제와 연질캅셀제 용출률 시험 결과Elution test results of tablets containing riding extract at pH 6.8 and soft capsules 시 간time Tab.Tab. S.Cap.S.Cap. 55 1.8±0.17 %1.8 ± 0.17% 15.4±8.42 %15.4 ± 8.42% 1010 2.3±0.21 %2.3 ± 0.21% 92.4±5.77 %92.4 ± 5.77% 2020 25.4±5.32 %25.4 ± 5.32% 99.6±0.57 %99.6 ± 0.57% 3030 43.7±7.22 %43.7 ± 7.22% 100.7±1.02 %100.7 ± 1.02% 4040 66.3±10.33 %66.3 ± 10.33% 99.8±1.32 %99.8 ± 1.32% 6060 87.3±12.18 %87.3 ± 12.18% 101.2±0.68 %101.2 ± 0.68%

표 1과 표 2에서 확인되는 바와 같이 각각의 pH 조건에서 승마추출물 함유 연질캅셀의 용출률이 정제의 용출률보다 높았으며 승마추출물 함유 연질캅셀의 경우 인체 흡수율이 크게 향상되어 약리효과를 크게 높일 수 있는 특징이 있다.As shown in Table 1 and Table 2, the elution rate of the soft capsule containing the horse riding extract was higher than the elution rate of the tablet under the respective pH conditions. There is this.

본 발명에 따른 승마추출물의 혼화조성물을 함유하는 연질캅셀제는 기존 정제 등에 비하여 현저히 향상된 약물 용출률을 나타내어, 인체 흡수율이 크게 향상되어 약리효과를 높일 수 있어서 새로운 치료제형으로 크게 기대된다.Soft capsules containing a mixed composition of horse riding extract according to the present invention shows a significantly improved drug dissolution rate compared to the conventional tablets, greatly improve the human absorption rate is expected to be greatly expected as a new therapeutic formulation.

Claims (4)

승마추출물 2∼40 중량%(27-데옥시악테인으로서 0.1∼2 중량%), 폴리에틸렌글리콜 30∼90 중량%, 농글리세린 5∼20 중량% 및 정제수 5∼15 중량%로 이루어지는 승마추출물의 혼화 조성물.Admixture of horseback riding extract consisting of 2-40% by weight (0.1-2% by weight of 27-deoxyactin), 30-90% by weight polyethylene glycol, 5-20% by weight glycerin and 5-15% by weight purified water Composition. 제 1항에 있어서, 폴리에틸렌글리콜은 폴리에틸렌글리콜 400을 사용함을 특징으로 하는 조성물.The composition of claim 1, wherein the polyethylene glycol uses polyethylene glycol 400. 승마추출물 2∼40 중량%(27-데옥시악테인으로서 0.1∼2 중량%), 폴리에틸렌글리콜 30∼90 중량%, 농글리세린 5∼20 중량% 및 정제수 5∼15 중량%를 가온하에 혼합하여 승마추출물을 혼화시키는 방법.Horse Riding Extract 2-40% by weight (0.1-2% by weight as 27-deoxyactin), 30-90% by weight polyethylene glycol, 5-20% by weight concentrated glycerin and 5-15% by weight purified water under riding How to admix the extract. 승마추출물 2∼40 중량%(27-데옥시악테인으로서 0.1∼2 중량%), 폴리에틸렌글리콜 30∼90 중량%, 농글리세린 5∼20 중량% 및 정제수 5∼15 중량%를 혼합하여 제조한 혼화 조성물을 통상의 방법으로 연질캅셀에 충진시켜서 제조한 승마추출물을 함유하는 연질캅셀제.Admixture prepared by mixing 2-40 wt% of horse riding extract (0.1-2 wt% as 27-deoxyactin), 30-90 wt% of polyethylene glycol, 5-20 wt% of concentrated glycerin, and 5-15 wt% of purified water A soft capsule containing a riding extract prepared by filling the composition into a soft capsule by a conventional method.
KR10-2000-0000948A 2000-01-10 2000-01-10 Miscible composition containing extract of black cohosh KR100366233B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR10-2000-0000948A KR100366233B1 (en) 2000-01-10 2000-01-10 Miscible composition containing extract of black cohosh

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2000-0000948A KR100366233B1 (en) 2000-01-10 2000-01-10 Miscible composition containing extract of black cohosh

Publications (2)

Publication Number Publication Date
KR20010068833A true KR20010068833A (en) 2001-07-23
KR100366233B1 KR100366233B1 (en) 2003-01-14

Family

ID=19637447

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-0000948A KR100366233B1 (en) 2000-01-10 2000-01-10 Miscible composition containing extract of black cohosh

Country Status (1)

Country Link
KR (1) KR100366233B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010106527A (en) * 2001-11-20 2001-12-07 성백원 Method of manufacturing cosmetic ingredient for skin whiteness from herb medicines
KR20030012002A (en) * 2001-07-30 2003-02-12 진양제약주식회사 Soft capsule containing Asiasari Radix extract

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101810421B1 (en) * 2016-03-28 2017-12-19 주식회사 화진바이오코스메틱 Method for producing pill for relieving menopausal symptoms containing flaxseed

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030012002A (en) * 2001-07-30 2003-02-12 진양제약주식회사 Soft capsule containing Asiasari Radix extract
KR20010106527A (en) * 2001-11-20 2001-12-07 성백원 Method of manufacturing cosmetic ingredient for skin whiteness from herb medicines

Also Published As

Publication number Publication date
KR100366233B1 (en) 2003-01-14

Similar Documents

Publication Publication Date Title
EP0095123B1 (en) Sustained release diethylpropion compositions
US5135752A (en) Buccal dosage form
US3806603A (en) Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm
RU2018305C1 (en) Method of preparing solid gelatin capsules
KR100634571B1 (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
JP2003081870A (en) Pharmaceutical formulation for thyroid hormone
AU2018251256B2 (en) Pullulan capsules
CA2613102A1 (en) Formulations of conjugated estrogens and bazedoxifene
US3039933A (en) Ethyl cellulose-polyethylene glycol tablet matrix
US8012506B2 (en) Tannate compositions, methods of making and methods of use
EP1433478B1 (en) Pharmaceutical formulae for thyroid hormones and procedures for obtaining them
KR100366233B1 (en) Miscible composition containing extract of black cohosh
JPH0840880A (en) Medicine on basis of ketoprofen in soft gelatin capsule medicine and its preparation
US5633005A (en) Dimeticon pastilles
JP3904617B2 (en) Method for producing laxative composition
DE10392164T5 (en) Oral pharmaceutical formulation
US3629394A (en) Pleasant tasting chewable tablets and their production
US8257746B2 (en) Tannate compositions, methods of making and methods of use
JPH0977675A (en) Crude drug-formulated foaming tablet
JPS59101420A (en) Rectal composition containing indomethacin
CN100358496C (en) 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof
US6926906B2 (en) Orally administrable pharmaceutical formulation
JP3355471B2 (en) Pain health tea and its production method
JPS61207329A (en) Soft capsule filled with hydrophilic substance
CN107510696A (en) For treating the pharmaceutical composition of NASH

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121211

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20131213

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20141202

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20151210

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20161208

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20181205

Year of fee payment: 17